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The appearance of counterfeit medicines in supply chains is a global public health problem that may seriously 
affect patients. Counterfeit drugs do not meet quality standards and do not declare their real composition 
and/or source for the purposes of fraud. They may be generic or innovative, they may contain genuine 
constituents in a fake packaging, or wrong ingredients, or inactive ingredients, or an incorrect quantity 
of the active substance. In Croatia, no cases of counterfeit medicines have been detected so far, but the 
Agency for Medicinal Products and Medical Devices has received 34 samples of medicines and other 
products for testing from Zagreb City Police. The samples included medicines for erectile dysfunction: 
sildenaﬁ l, tadalaﬁ l, and vardenaﬁ l. Twenty-three samples of tablets without marketing authorisation in 
Croatia were tested with high-performance liquid chromatography (HPLC) for the declared sildenaﬁ l and 
tadalaﬁ l content. Samples labelled 1 (batch T/33), 3 (batch T/33), 5 (batch 4), 6 (batch M0016J), 10 (batch 
T-070235), 12 (batch T-070544), 15 (batch 314833201), 16 (batch 832718474), and 17 (batch 504830028) 
containing sildenaﬁ l and samples labelled 20 (batch 070356), 21 (batch 05668), and 22 (batch T 378 5) 
containing tadalaﬁ l did not contain the active substance within the acceptable 95 % to 105 % margin of 
deviation from the declared content. While most samples cannot be described as fake with a reasonable 
amount of certainty, there is still a suspicion of counterfeit. A correct conclusion can be drawn only with 
the assistance of the manufacturers and by conducting additional laboratory tests.
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According to the World Health Organization 
(WHO) deﬁ nition, counterfeit medicines form part 
of a broader category of pharmaceutical products 
which do not meet quality standards in force, with the 
difference that they are deliberately and fraudulently 
mislabelled with respect to their real composition 
and/or source. Counterfeit medicines may be both 
branded and generic and may contain genuine 
constituents in a fake packaging, or wrong ingredients, 
or inactive ingredients, or an incorrect quantity of the 
active substance (1, 2). The use of such medicines 
poses a health risk in that the intended effect of a 
medicinal product is not achieved, which may result 
in unexpected adverse effects, anaphylaxis, resistance 
to medicinal product, or other health problems (3-
5). Most industrialised countries with an efﬁ cient 
system and market surveillance regulation have a 
low percentage of such products, mostly below 1 %, 
whereas in many countries of Africa and parts of 
Asia and Latin America the market share of such 
products exceeds 30 % (6-10). Counterfeit medicines 
in the European Union are mostly the “lifestyle” 
drugs, including medicinal products for erectile 
dysfunction and obesity (11). Apart from these, 
there are fake medicines for oncological, cardiac, 
psychiatric, and infectious diseases (12-14). This trend 
70
in pharmaceutical crime may further rise, because 
the driving force behind it are high gains and high 
sales accompanied by utter disregard for the health of 
patients, which makes it a global problem (15-18).
In Croatia, no cases of counterfeit medicines have 
been detected so far in licensed pharmacies or in 
wholesale chains. But on the illegal drug market 34 
samples have been seized. The products were classiﬁ ed 
in three groups, the ﬁ rst of which included products 
authorised for marketing in Croatia, the second 
comprised products without marketing authorisation, 
and the third products which are not medicines 
but rather medical devices or dietary supplements 
(Figure 1). The ﬁ rst and the second group consisted 
of 26 samples indicated for the treatment of erectile 
dysfunction, declared to contain active substances 
sildenaﬁ l, tadalaﬁ l, or vardenaﬁ l (Figure 2).
The purpose of this study was to determine the 
safety of samples identiﬁ ed as sildenaﬁ l and taldalaﬁ l 
in view of possible counterfeiting.
MATERIALS AND METHODS
The samples were submitted to the Agency as the 
regulatory authority by Zagreb Police Department. 
High performance liquid chromatography (HPLC) 
was used to separate sildenaﬁ l and tadalaﬁ l from 
their potential degradation products, process-related 
impurities, and formulation constituents according 
to manufacturer instructions. Sildenaﬁ l and tadalaﬁ l 
were quantiﬁ ed by comparing chromatographic peak 
areas of sample solutions with reference standard 
solutions. The following reference substances were 
used to prepare reference solutions: sildenaﬁ l citrate; 
Pﬁ zer (USA), lot 0015-QSC-23 and tadalaﬁ l; Lilly 
(USA); lot 991085.
To determine active substances in tablets of the 
illegal products, we used a liquid chromatograph 
equipped with a column oven, a variable wavelength 
ultraviolet absorption detector, and a sample injection 
system. Sildenaﬁ l and tadalaﬁ l content in test samples 
was calculated as percentage of declared content of 
sildenaﬁ l and tadalaﬁ l per tablet.
Chromatographic conditions for sildenaﬁ l and 
tadalaﬁ l identiﬁ cation are given in Table 1.
RESULTS AND DISCUSSION
If a ﬁ nished medicinal product is licensed for 
marketing in Croatia and the manufacturer is based 
outside Croatia, the distributor or the importer shall 
apply to the Agency for quality verification for 
every imported batch or for Agency’s consent if its 
quality has been tested in the European Union. A 
comparison with samples licensed for marketing in 
Croatia (sildenaﬁ l 50 mg tablets, sildenaﬁ l 100 mg 
tablets, tadalaﬁ l 20 mg tablets, vardenaﬁ l 10 mg 
tablets, vardenaﬁ l 20 mg tablets) showed that samples 
submitted by the police were not authorised for 
marketing in Croatia, and were most likely intended 
for distribution in countries other than Croatia or for 
an illegal drug market. 
Medicinal products lacking marketing authorisation 
for Croatia may be imported only with a special import 
license issued by the Agency. Since its foundation, the 
Figure 1 Medicines and other products from illegal supply
Figure 2  Medicinal products from illegal supply according to 
their active pharmaceutical ingredients
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Agency has never issued a special import licence for 
any of the reference medicinal products (C/Finegra 
100 mg tablets1, Sildoﬁ l 100 mg tablets2, Cobra 100 
mg tablets3, KamagraTM 100 mg tablets4, Novagra forte 
100 mg tablets5, Vega 100 mg tablets6, Venegra 100 
mg tablets7, Virecta 100 mg tablets8, Apcalis plus 20 
mg tablets9).
Other submitted samples not identiﬁ ed as medicines 
or medical devices are not within Agency’s scope of 
responsibility (Figure 1). One can not discard the 
possibility that some of these products are classiﬁ ed 
as medicines in other countries. This group of 
products includes Femi-X10 tablets, manufactured 
by Danish Pharmaceutical Industries Ltd., that have 
been authorised for marketing in Croatia as a dietary 
supplement intended to increase libido in women. 
Other products, Wollust Tropfen, Erotic Fluid, and 
Original Inverma Yohimbinum11 were manufactured 
by Inverma Chemie, Germany. According to the 
declaration, these products are intended to increase 
potency and contain ginseng extract and yohimbine 
at very low concentrations otherwise typical of 
homeopathic products.
During authorisation of authentic medicines, the 
Agency for Medicinal Products and Medical Devices 
approved the manufacturer’s speciﬁ cations which were 
used in the Agency for testing the ﬁ rst group of drugs. 
The tests included veriﬁ cation and quantiﬁ cation of 
1 Manufacturer is not speciﬁ ed
2 Future Pharmaceuticals
3 MB C
4 Aajanta Pharma Limited
5 Brown & Burk (UK) Ltd.
6 Manufacturer is not speciﬁ ed





the active substance against reference substance using 
high-performance liquid chromatography (HPLC).
The Agency does not possess any manufacturers’ 
documentation or analytical instructions for medicines 
lacking marketing authorisation in Croatia. As, 
according to the declaration, the medicines from the 
second group contained the same active substance as 
the authorised medicinal products, we used the same 
methods as for licensed ﬁ nished medicinal products 
to verify and quantify them. As not all submitted 
batches had enough samples to meet manufacturer’s 
instructions for analysis, we tested only two samples 
per batch, and the results were not statistically 
analysed.
Sildenaﬁ l samples were prepared in accordance 
with the procedure for Viagra® tablets manufactured 
by Pﬁ zer. Two samples containing one tablet each 
were tested from each batch (Table 2, Figure 3).
Tadalafil samples, again two per batch, were 
prepared by combining three individual tablets in 
a 250 mL volumetric ﬂ ask and processing them in 
accordance with the procedure for Cialis tablets 
manufactured by Lilly (Table 2, Figure 4). 
The presence of the active substance has been 
conﬁ rmed in all tested samples, so in qualitative terms 
all samples conformed to declarations. Table 2 and 
Figure 5 show the quantitative composition in the tested 
samples of the ﬁ rst and second group of medicines. 
Samples labelled 1 (batch T/33), 3 (batchT/33), 5 
(batch 4), 6 (batch M0016J), 10 (batch T-070235), 
12 (batch T-070544), 15 (batch 314833201), 16 
(batch 832718474), 17 (batch 504830028) 20 (batch 
070356), 21 (batch 05668), and 22 (batch T 378 5), 
contained the active substance outside the acceptable 
95 % to 105 % margin of deviation from the declared 
value. These deviations conﬁ rmed drug defects and 
the suspicion of counterfeit (Figure 6).
Table 1 Chromatographic conditions for sildenaﬁ l and tadalaﬁ l identiﬁ cation
Sildenaﬁ l Tadalaﬁ l
Column
Symmetry Shield RP 18, 
150 mm x 3.9 mm; 5 µm
Symmetry Shield RP 18, 
150 mm x 3.9 mm; 5 µm
Detector UV 290 nm UV 285 nm
Column temperature 30 °C 30 °C
Injection volume 20 µL 10 µL
Buffer
0.05 mol L-1 triethylamine solution modiﬁ ed 
to pH 3.0±0.05 with 1:10 diluted phosphate 
acid or 0.01 mol L-1 NaOH
Mobile phase buffer : acetonitrile : methanol (58 :17 : 25);
acetonitrile : water with 0.1 % (v/v) 
triﬂ uoroacetic acid (35 : 65)
Flow rate 1.0 mL min-1 1.0 mL min-1
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Figure 6  Deviation from active substance content in tablet 
samples
Figure 3  A typical chromatogram of sildenaﬁ l sample and 
reference standard 
Figure 4  A typical chromatogram of tadalaﬁ l sample and 
reference standard
Figure 5 Test results of sildenaﬁ l and tadalaﬁ l tablets
CONCLUSION
Even if test results fall within acceptable margins, 
one can safely verify the authenticity of a medicine 
only after receiving manufacturer’s opinion based on 
complete batch data. Manufacturers alone possess 
complete data and in case of suspicion can run a 
series of additional target tests in their laboratories, 
including additional tests for purity proﬁ les of active 
substances, excipients used in the finished drug 
product, type and material of primary and secondary 
packaging, or the quality and credibility of printing. 
These additional tests can make it easier and quicker 
to see whether a drug is authentic or fake; indeed, they 
are sometimes the only means to do this. Sufﬁ ciently 
discriminating analytical techniques are also needed, 
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4 tablets in a blister 
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4 C/Finegra not speciﬁ ed
sildenaﬁ l /
100 mg





5 Cobra 100 mg MB C
sildenaﬁ l /
100 mg












4 tablets in a blister 
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4 tablets in a blister 












4 tablets in a blister 







10 Vega 100 not speciﬁ ed
sildenaﬁ l /
100 mg





11 Vega 100 not speciﬁ ed
sildenaﬁ l /
100 mg





12 Vega 100 not speciﬁ ed
sildenaﬁ l /
100 mg





13 Vega 100 Asia not speciﬁ ed
sildenaﬁ l /
100 mg










4 tablets in a blister 












4 tablets in a blister 












4 tablets in a blister 






17 VIAGRA 50 mg Pﬁ zer Inc.
sildenaﬁ l /
50 mg
4 tablets in a blister 






18 Virecta EVA Pharma
sildenaﬁ l /
100 mg
3 tablets in a blister 






19 Virecta EVA Pharma
sildenaﬁ l /
100 mg
3 tablets in a blister 






20 Apcalis Plus 20 MS Pharma
tadalaﬁ l /
20  mg
2x2 tablets in a blister 






21 Cialis® 20 mg Lilly ICOS
tadalaﬁ l /
20  mg
2x2 tablets in a blister 

















23 Tadlis 20 Orient Pharma
tadalaﬁ l /
20  mg
2x2 tablets in a blister 
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such as the near infrared spectroscopy (NIR), which 
is a mandatory method for ﬁ ngerprint identiﬁ cation 
of medicinal products by manufacturers (19-21). Such 
tests are designed to identify the manufacturing site 
and deviations from manufacturer’s standards for each 
manufactured batch.
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Sažetak
IDENTIFIKACIJA KRIVOTVORENIH LIJEKOVA ZA EREKTILNU DISFUNKCIJU IZ ILEGALNOG 
LANCA OPSKRBE
Pojava krivotvorenih lijekova u lancima opskrbe globalni je javnozdravstveni problem koji može imati 
ozbiljnih posljedica za pacijenta. Krivotvoreni lijekovi ne zadovoljavaju propisane standarde kakvoće 
te su u svrhu prijevare drugačije deklarirani u odnosu na njihov stvarni sastav i/ili podrijetlo. Mogu biti 
generički, ili inovativni, mogu sadržavati ispravne sastojke, ali pogrešno pakiranje, pogrešne sastojke, 
ne sadržavati djelatnu tvar ili ne sadržavati dovoljnu količinu djelatne tvari. U Hrvatskoj do sada nisu 
zabilježeni slučajevi krivotvorenih lijekova, ali je Agencija za lijekove i medicinske proizvode od policijske 
uprave Zagrebačke zaprimila 34 uzorka lijeka i ostalih proizvoda u svrhu ispitivanja. Od lijekova, radilo 
se o lijekovima za erektilnu disfunkciju sildenaﬁ lu, tadalaﬁ lu i vardenaﬁ lu. 23 uzorka tableta koji nemaju 
odobrenje za stavljanje lijeka u promet u Hrvatskoj ispitana su metodom tekućinske kromatograﬁ je visokog 
učinka (HPLC) na deklarirani sadržaj sildenaﬁ la i tadalaﬁ la. Ustanovljeno je da uzorci pod oznakama 1 
(serija T/33), 3 (serijaT/33), 5 (serija 4), 6 (serija M0016J), 10 (serija T-070235), 12 (serija T-070544), 15 
(serija 314833201), 16 (serija 832718474), 17 (serija 504830028) koji su sadržavali sildenaﬁ l te uzorci 20 
(serija 070356), 21 (serija 05668), 22 (serija T 378 5) i 23 (702099) koji su sadržavali tadalaﬁ l, ne sadržavaju 
djelatnu tvar unutar prihvatljivih granica odstupanja od 95 % do 105 % od deklarirane vrijednosti. Iako se 
ne može sa sigurnosti za većinu uzoraka reći da se radi o krivotvorini, ipak se može govoriti o sumnji na 
krivotvorinu, a cjeloviti zaključak može se izvesti jedino uz suradnju i mišljenje proizvođača te provedbom 
dodatnih laboratorijskih ispitivanja.
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